Elanco Animal Health Inc

Pharmaceutical Preparations·INDIANAPOLIS, IN·FY end 12/31·CIK 1739104

CEO Pay Ratio

181:1

Jeffrey Simmons

CEO Total Comp

$14.9M

Jeffrey Simmons

Median Employee

$82,675

Revenue

$4.7B

FY 2025

Net Income

-$232.0M

FY 2025

Free Cash Flow

$284.0M

FY 2025

Net Margin

-4.9%

Insider Net (180d)

0 buys / 0 sales

CEO Pay Accountability

CEO comp as % of net income

-6.43%

For every $1,000 of profit, $-64.34 flows to the CEO.

CEO comp as % of buybacks

—

No buyback data for the most recent fiscal year.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$4.7B	$4.4B	$4.4B	$4.4B	$4.8B
Gross Profit	$2.6B	—	—	—	—	—
Operating Income	—	—	—	—	—	—
Net Income	-$232.0M	$338.0M	-$1.2B	-$65.0M	-$472.0M
Operating CF	$560.0M	$541.0M	$271.0M	$452.0M	$483.0M
Capex	$276.0M	$147.0M	$140.0M	$137.0M	$126.0M
Free Cash Flow	$284.0M	$394.0M	$131.0M	$315.0M	$357.0M
Buybacks	—	—	—	—	—	—
Dividends	—	—	—	—	—	—

Gross Margin	55.0%	—	—	—	—	—
Operating Margin	—	—	—	—	—	—
Net Margin	-4.9%	7.6%	-27.9%	-1.5%	-9.9%
FCF Margin	6.0%	8.9%	3.0%	7.1%	7.5%
R&D / Revenue	7.8%	7.7%	7.4%	7.3%	7.7%
Effective Tax	-3.6%	30.7%	-3.0%	-47.7%	16.8%
Debt / Equity	0.57	1.41	1.85	1.55	1.64
Buybacks / FCF	—	—	—	—	—	—

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Jeffrey SimmonsPresident and Chief Executive Officer	—	—	—	—	—	$14.9M
Ramiro CabralExecutive Vice President, President International	$650.0K	$1.5M	$500.0K	$566.8K	$27.0K	$3.2M
Ellen de BrabanderExecutive Vice President, Innovation and Regulatory	—	—	—	—	—	—
Robert VanHimbergenExecutive Vice President and Chief Financial Officer	—	—	—	—	—	—
Tim BettingtonExecutive Vice President, Global Strategy and Market Development	—	—	—	—	—	—
Todd YoungFormer Executive Vice President and Chief Financial Officer	—	—	—	—	—	—